Wealth Enhancement Advisory Services LLC Invests $262,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Wealth Enhancement Advisory Services LLC has acquired a stake in Arrowhead Pharmaceuticals, purchasing 15,580 shares valued at approximately $262,000.
• Several institutional investors have increased their holdings in Arrowhead Pharmaceuticals, including UBS AM, which boosted its position by 138.0% in the first quarter.
• Analysts currently have a consensus rating of “Moderate Buy” on Arrowhead Pharmaceuticals, with an average price target of $43.14.

Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,580 shares of the biotechnology company's stock, valued at approximately $262,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock worth $60,962,000 after acquiring an additional 2,774,933 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after acquiring an additional 1,018,273 shares during the last quarter. Aberdeen Group plc boosted its position in shares of Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock worth $13,668,000 after acquiring an additional 622,752 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock valued at $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Finally, Public Sector Pension Investment Board purchased a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $5,094,000. 62.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Royal Bank Of Canada lowered their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $36.06 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $39.42. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -28.17 and a beta of 1.13. The company has a 50 day simple moving average of $26.20 and a two-hundred day simple moving average of $18.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the firm posted ($1.38) earnings per share. As a group, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the company's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares in the company, valued at approximately $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 60,000 shares of company stock valued at $1,725,000 in the last three months. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.